$RKDA

Arcadia Biosciences, Inc.

CIK:0001469443|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenues:
Total revenues	$ 1,443,000	$ 1,455,000	$ 2,543,000	$ 2,655,000
Operating expenses (income):
Cost of revenues	812,000	824,000	1,512,000	1,506,000
Research and development	0	9,000	0	9,000
Gain on sale of intangible assets	0	0	0	(750,000)
Change in fair value of contingent consideration	0	(1,000,000)	0	(2,000,000)
Selling, general and administrative	1,127,000	2,123,000	2,306,000	3,861,000
Total operating expenses	1,939,000	1,956,000	3,818,000	2,626,000
(Loss) Income from continuing operations	(496,000)	(501,000)	(1,275,000)	29,000
Interest income	2,000	9,000	7,000	216,000
Credit loss	0	(4,489,000)	0	(4,489,000)
Other (loss) income, net	(2,781,000)	1,071,000	(4,285,000)	1,071,000
Loss on January 2026 Inducement Offer	0	0	(2,877,000)	0
Valuation loss on June 2026 PIPE	(5,423,000)	0	(5,423,000)	0
Change in fair value of common stock warrant and option liabilities	3,083,000	(548,000)	4,274,000	1,314,000
Issuance and offering costs	(651,000)	0	(1,072,000)	0
Net (loss) income from continuing operations	$ (6,266,000)	$ (4,458,000)	$ (10,651,000)	$ (1,859,000)
Net loss per share attributable to common stockholders:
Basic	$ (2.09)	$ (3.26)	$ (4.19)	$ (1.36)
Diluted	$ (2.09)	$ (3.26)	$ (4.19)	$ (1.36)
Weighted-average number of shares used in per share calculations:
Weighted average shares - Basic	2,992,555	1,367,040	2,540,234	1,366,553
Weighted average shares - Diluted	2,992,555	1,367,040	2,540,234	1,366,553
Product
Revenues:
Total revenues	$ 1,443,000	$ 1,455,000	$ 2,543,000	$ 2,655,000

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,266,000)	$ (4,385,000)	$ (4,458,000)	$ 2,599,000	$ (10,651,000)	$ (1,859,000)	$ (2,300,000)
Adjustments to reconcile net income to cash used in operating activities:
Change in fair value of common stock warrant and option liabilities	(3,083,000)		548,000		(4,274,000)	(1,314,000)
Change in fair value of contingent consideration					0	(2,000,000)
Issuance and offering costs	651,000		0		1,072,000	0
Valuation loss on June 2026 PIPE	5,423,000		0		5,423,000	0
Loss on January 2026 Inducement Offer	0		0		2,877,000	0
Depreciation	0		15,000		8,000	28,000
Lease amortization					0	117,000
Amortization of note receivable					0	(69,000)
Gain on sale of intangible assets	0		0		0	(750,000)
Gain on receipt of Above Food Ingredients, Inc. common stock					0	(1,067,000)
Unrealized loss subsequent to receipt of Above Food Ingredients, Inc. common stock					4,304,000	0
Stock-based compensation	14,000		86,000		29,000	164,000
Credit loss	0		4,489,000		0	4,489,000
Changes in operating assets and liabilities:
Accounts receivable and other receivables					(134,000)	(417,000)
Inventories					282,000	(585,000)
Prepaid expenses and other current assets					84,000	544,000
Other noncurrent assets					0	(56,000)
Accounts payable and accrued expenses					(431,000)	(630,000)
Amounts due to related parties					0	(30,000)
Other current liabilities					(7,000)	(57,000)
Operating lease liabilities					0	(129,000)
Net cash used in operating activities					(1,418,000)	(3,621,000)	(4,700,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of intangible assets					0	750,000
Net cash provided by investing activities					0	750,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from ESPP purchases					0	5,000
Net cash provided by financing activities					5,337,000	5,000
Net increase (decrease) in cash and cash equivalents					3,919,000	(2,866,000)
Cash and cash equivalents - beginning of period		$ 259,000		$ 4,242,000	259,000	4,242,000	4,242,000
Cash and cash equivalents - end of period	$ 4,178,000		$ 1,376,000		4,178,000	1,376,000	$ 259,000
NONCASH INVESTING AND FINANCING ACTIVITIES:
Fair value of Above Food Ingredients, Inc. common stock received					0	3,067,000
January 2026 Inducement Offer [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from January 2026 Inducement Offer					2,082,000	0
Payments of offering costs					(350,000)	0
NONCASH INVESTING AND FINANCING ACTIVITIES:
Preferred investment options issued to placement agent and included in offering costs					71,000	0
Warrant and option modifications included in Loss on January 2026 Inducement Offer					555,000	0
June 2026 PIPE [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from June 2026 PIPE					4,000,000	0
Payments of offering costs					(395,000)	0
NONCASH INVESTING AND FINANCING ACTIVITIES:
Accrued legal fees included in offering costs					55,000	0
Preferred investment options issued to placement agent and included in offering costs					$ 201,000	$ 0

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 4,178	$ 259
Short-term investments	0	4,304
Accounts receivable and other receivables, net of allowance for credit loss of $559 as of June 30, 2026 and December 31, 2025	559	425
Inventories	930	1,212
Prepaid expenses and other current assets	72	156
Total current assets	5,739	6,356
Property and equipment, net	0	8
Intangible assets, net	39	39
Other noncurrent assets	115	143
Total assets	5,893	6,546
Current liabilities:
Accounts payable and accrued expenses	1,383	1,789
Total current liabilities	1,646	2,059
Common stock warrant and option liabilities	3,614	347
Total liabilities	5,260	2,406
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.001 par value - 150,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 2,181,715 and 1,373,120 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	66	65
Additional paid-in capital	292,435	285,292
Accumulated deficit	(291,868)	(281,217)
Total stockholders' equity	633	4,140
Total liabilities and stockholders’ equity	5,893	6,546
Nonrelated Party [Member]
Current liabilities:
Other current liabilities	$ 263	$ 270